sur ABSCIENCES (EPA:AB)
AB Science Stock Coverage Initiated by Maxim Group with €4 Target Price
AB Science SA has announced that its stock is now covered by Maxim Group, a U.S.-based investment bank. This coverage began with a study titled "Mastering Mast Cell Inhibition for Neurodegenerative Diseases Starting with ALS," recommending a buy rating with a target price of €4.00.
Maxim Group's study highlights masitinib's promising results in treating neurodegenerative diseases. The study emphasizes the positive risk-benefit profile of masitinib, supported by data from progressive multiple sclerosis (MS) and mild Alzheimer's disease (AD), which further validates its neuroprotective potential.
This initiation by Maxim Group adds to the consensus from other financial analysts such as Chardan, In Extenso Finance, and DNA Finance, enriching the analytical coverage of AB Science's stock. This development represents a significant milestone for the company in enhancing its market presence and improving investor confidence.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de ABSCIENCES